Advertisment

The Impact of COVID-19 on Influenza Vaccines: The Transition from Quadrivalent to Trivalent Formulations

author-image
Ayanna Amadi
New Update
NULL

The Impact of COVID-19 on Influenza Vaccines: The Transition from Quadrivalent to Trivalent Formulations

Advertisment

In the wake of the COVID-19 pandemic, global health landscapes have seen a significant shift, with changes affecting even the realm of influenza viruses. One such change involves the Yamagata lineage of influenza B viruses, which has not been observed since March 2020. With global efforts to locate the strain proving futile, health experts are now contemplating the removal of the Yamagata component from flu vaccines. This would transition vaccines from a four-flu to a trivalent formulation, significantly altering the current landscape of influenza prevention.

Advertisment

The Missing Yamagata Lineage

The Yamagata lineage of the influenza B virus has seemingly vanished since the onset of the pandemic. As a result, its inclusion in flu vaccines is now deemed unnecessary. Officially removing it from vaccines will solidify this sentiment and mark a significant shift in global health strategies. The absence of this strain is believed to be due to changes in human behavior during the COVID-19 pandemic, with most experts now convinced that it is no longer circulating.

The Transition to Trivalent Vaccines

Advertisment

The shift from a quadrivalent to a trivalent flu vaccine is not as straightforward as it may seem. It requires its own licensure and regulatory pipelines, which may pose challenges for manufacturers. It is estimated that it might take until the 2025-26 season for manufacturers to fully transition to trivalent vaccines in the Northern Hemisphere.

Despite these challenges, some major flu vaccine producers are on track to deliver trivalent vaccines to the U.S. in time for the 2024-25 flu season. This transition should make flu vaccines cheaper and improve global access, which is a significant step forward in global health equity.

The Risks and Future Considerations

Advertisment

While the transition to a trivalent vaccine seems promising, it is not without risks. There is a small but serious danger that the Yamagata lineage could be inadvertently reintroduced to the world. Therefore, researchers remain cautious about the potential reappearance of the strain.

In addition, future changes to flu vaccines might involve the incorporation of a second H3N2 strain. However, this adjustment poses additional challenges and is currently under discussion among health experts.

Influenza and RSV Coinfections in Adults

Advertisment

On a related note, the Canadian Immunization Research Network has reported on the clinical features and outcomes of influenza and RSV (Respiratory Syncytial Virus) coinfections in hospitalized adults. Over three influenza seasons, 33 cases of RSV and influenza coinfection were identified, with a 12.1% mortality rate. Older adults, especially those over 65 with a high comorbidity burden and frailty, are at higher risk for complications from these coinfections.

The report emphasizes the importance of vaccination against influenza to prevent infection and reduce severity. It also highlights the approval of the first two vaccines to prevent RSV in adults, indicating another shift in global influenza prevention strategies.

In conclusion, the global health landscape is undergoing substantial changes in response to the COVID-19 pandemic. The transition to a trivalent flu vaccine reflects these changes and sets a new direction for influenza prevention in the coming years.

Advertisment
Chat with Dr. Medriva !